Platelet/Thrombocyte

Dipyridamole effectively inhibits the uptake of adenosine into cells (red blood cells, platelets, endothelial cells). Thus dipyridamole increases the local concentration of adenosine, which accumulates in the microenvironment of a growing thrombus.

The Formulation of Aggrenox®

Dipyridamole's antiplatelet action complements that of ASA. By inhibiting cellular uptake of adenosine, dipyridamole increases levels of circulating adenosine and intraplatelet cAMP, a potent inhibitor of platelet aggregation. Dipyridamole also inhibits the phosphodiesterase responsible for breakdown of cGMP, which has an anti-aggregating effect.